Article | Published:

Neotuberostemonine inhibits the differentiation of lung fibroblasts into myofibroblasts in mice by regulating HIF-1α signaling

Acta Pharmacologica Sinica | Download Citation

Subjects

Abstract

Pulmonary fibrosis may be partially the result of deregulated tissue repair in response to chronic hypoxia. In this study we explored the effects of hypoxia on lung fibroblasts and the effects of neotuberostemonine (NTS), a natural alkaloid isolated from Stemona tuberosa, on activation of fibroblasts in vitro and in vivo. PLFs (primary mouse lung fibroblasts) were activated and differentiated after exposure to 1% O2 or treatment with CoCl2 (100 μmol/L), evidenced by markedly increased protein or mRNA expression of HIF-1α, TGF-β, FGF2, α-SMA and Col-1α/3α, which was blocked after silencing HIF-1α, suggesting that the activation of fibroblasts was HIF-1α-dependent. NTS (0.1–10 μmol/L) dose-dependently suppressed hypoxia-induced activation and differentiation of PLFs, whereas the inhibitory effect of NTS was abolished by co-treatment with MG132, a proteasome inhibitor. Since prolyl hydroxylation is a critical step in initiation of HIF-1α degradation, we further showed that NTS treatment reversed hypoxia- or CoCl2-induced reduction in expression of prolyl hydroxylated-HIF-1α. With hypoxyprobe immunouorescence staining, we showed that NTS treatment directly reversed the lower oxygen tension in hypoxia-exposed PLFs. In a mouse model of lung fibrosis, oral administration of NTS (30 mg·kg-1·d-1, for 1 or 2 weeks) effectively attenuated bleomycin-induced pulmonary fibrosis by inhibiting the levels of HIF-1α and its downstream profibrotic factors (TGF-β, FGF2 and α-SMA). Taken together, these results demonstrate that NTS inhibits the protein expression of HIF-1α and its downstream factors TGF-β, FGF2 and α-SMA both in hypoxia-exposed fibroblasts and in lung tissues of BLM-treated mice. NTS with anti-HIF-1α activity may be a promising pharmacological agent for the treatment of pulmonary fibrosis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , . Fibrosis - a common pathway to organ injury and failure. N Engl J Med 2015; 372: 1138–49.

  2. 2.

    , , . Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012; 5: 11–35.

  3. 3.

    , , , . The cytokines of pulmonary fibrosis: much learned, much more to learn. Cytokine 2015; 74: 88–100.

  4. 4.

    , . Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med 2013; 64: 265–76.

  5. 5.

    , , , . Targeted therapy for idiopathic pulmonary fibrosis: where to now? Drugs 2016; 76: 291–300.

  6. 6.

    , , . Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol Mech Dis 2014; 9: 157–79.

  7. 7.

    , , , , , , et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 29: 2071–82.

  8. 8.

    , , , , , , et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–9.

  9. 9.

    , , . Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol 2013; 231: 273–89.

  10. 10.

    , , , , , , et al. Recent developments in myofibroblast biology paradigms for connective tissue remodeling. Am J Pathol 2012; 180: 1340–55.

  11. 11.

    , , . JunD and HIF-1α mediate transcriptional activation of angiotensinogen by TGF-β1 in human lung fibroblasts. FASEB J 2009; 23: 1655–62.

  12. 12.

    , , , , , , et al. Hypoxia-inducible factor-1α mediates TGF-induced PAI-1 production in alveolar macrophages in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2011; 300: L740–52.

  13. 13.

    , , , , , . Interdependence of HIF-1α and TGF-β/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol 2011; 300: F898–905.

  14. 14.

    , , , , , , et al. Cross regulation between hypoxia-inducible transcription factor-1α (HIF-1α) and transforming growth factor (TGF)- β1 mediates nickel oxide nanoparticles (NiONPs)-induced pulmonary fibrosis. Am J Transl Res 2015; 7: 2364–78.

  15. 15.

    . Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551–78.

  16. 16.

    , , , , , , et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1α in disease pathogenesis. Am J Respir Crit Care Med 2007; 176: 1108–19.

  17. 17.

    , , , , , . Effcient translation of mouse hypoxia-inducible factor-1α under normoxic and hypoxic conditions. Biochim Biophys Acta 2000; 1493: 125–34.

  18. 18.

    , . HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 2011; 183: 152–6.

  19. 19.

    , , , , , , et al. Chronic intermittent hypoxia worsens bleomycin-induced lung fibrosis in rats. Respir Physiol Neurobiol 2017. pii: S1569-9048(16) 30325-1.

  20. 20.

    , , , , , , et al. Hypoxia-inducible factor-1α in hepatic fibrosis: A promising therapeutic target. Biochimie 2015; 108: 1–7.

  21. 21.

    , , , , , , et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810–20.

  22. 22.

    , , , , , , et al. Signalling pathways involved in hypoxia-induced renal fibrosis. J Cell Mol Med 2017; 21: 1248–59.

  23. 23.

    , , . Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58: 2351–66.

  24. 24.

    , , , , . Hypoxia induces differentiation of pulmonary artery adventitial fibroblasts into myofibroblasts. Am J Physiol Cell Physiol 2004; 286: C416–25.

  25. 25.

    , , , . Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32: 2–8.

  26. 26.

    , . Targeting hypoxia inducible factors-1a as a novel therapy in fibrosis. Front Pharmacol 2017; 8: 326–33.

  27. 27.

    , , , , , . Antitussive and central respiratory depressant effects of Stemona tuberose. J Ethnopharmacol 2010; 128: 679–84.

  28. 28.

    , , , , . Antitussive activity of Stemona alkaloids from Stemona tuberose. Planta Med 2003; 69: 914–20.

  29. 29.

    , , , , , , et al. Inhibitory effects of Stemona tuberosa on lung inflammation in a subacute cigarette smoke induced mouse model. BMC Complement Altern Med 2014; 14: 513–24.

  30. 30.

    , , , , , , et al. Neotuberostemonine attenuates bleomycin-induced pulmonary brosis by suppressing the recruitment and activation of macrophages. Int Immunopharmacol 2016; 36: 158–64.

  31. 31.

    , . Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723–37.

  32. 32.

    , , , , , . Seven new alkaloids from the roots of stemona tuberose. Tetrahedron 2014; 70: 967–74.

  33. 33.

    , . Transcriptional regulation of tropoelastin expression in rat lung broblasts: changes with age and hyperoxia. Am J Physiol 1998; 274: 940–50.

  34. 34.

    , , . Role of insulin-like growth factor II receptor in transdifferentiation of free silica-induced primary rat lung fibroblasts. Biomed Environ Sci 2013; 26: 979–85.

  35. 35.

    , , . Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467–70.

  36. 36.

    , , , , , , et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 2008; 44: 507–17.

  37. 37.

    , , , , , . Multiwall carbon nanotubes directly promote fibroblast-myobroblast and epithelial-mesenchymal transitions through the activation of the TGF-β/Smad signaling pathway. Small 2015; 11: 446–55.

  38. 38.

    , , , . Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem 2005; 280: 43000–9.

  39. 39.

    , , , , , , et al. Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2016; 310: L249–62.

  40. 40.

    , , , , , , et al. MiR-210 promotes IPF fibroblast proliferation in response to hypoxia. Am J Physiol Lung Cell Mol Physiol 2014; 307: 283–94.

  41. 41.

    , , , , , , et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med 2015; 192: 1462–74.

  42. 42.

    , , , , , , et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976–85.

  43. 43.

    , . Transforming growth factor-β: master regulator of the respiratory system in health and disease. Am J Respir Cell Mol Biol 2016; 54: 647–55.

  44. 44.

    , , , , . Basic fibroblast growth factor activates β-catenin/RhoA signaling in pulmonary fibroblasts with chronic obstructive pulmonary disease in rats. Mol Cell Biochem 2016; 423: 165–74.

  45. 45.

    , , , , . Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 2001; 20: 5197–206.

  46. 46.

    , , , , , , et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468–72.

  47. 47.

    , , , , , , et al. HIF-1α targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001; 292: 464–8.

  48. 48.

    , . The von Hippel–Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003; 13: 83–9.

  49. 49.

    , , , , , , et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1α and HIF-2α expression in lung epithelial cells. J Biol Chem 2004; 279: 14871–8.

  50. 50.

    , , , , . Constitutive/hypoxic degradation of HIF-1α proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. J Biol Chem 2007; 282: 15498–505.

Download references

Acknowledgements

This work was funded by the National New Drug Innovation Major Project of China (2011ZX09307-002-02).

Author information

Author notes

    • Xin-miao Lv
    •  & Ming-dan Li

    These authors contributed equally to this work.

Affiliations

  1. State Key Laboratory of Natural Medicines, Research Department of Pharmacognosy, China Pharmaceutical University, Nanjing 211198, China

    • Xin-miao Lv
    • , Ming-dan Li
    • , Si Cheng
    • , Bao-lin Liu
    • , Kang Liu
    • , Chao-feng Zhang
    • , Xiang-hong Xu
    •  & Mian Zhang

Authors

  1. Search for Xin-miao Lv in:

  2. Search for Ming-dan Li in:

  3. Search for Si Cheng in:

  4. Search for Bao-lin Liu in:

  5. Search for Kang Liu in:

  6. Search for Chao-feng Zhang in:

  7. Search for Xiang-hong Xu in:

  8. Search for Mian Zhang in:

Corresponding authors

Correspondence to Bao-lin Liu or Mian Zhang.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/aps.2017.202